Specifically, patients with treatment resistant depression display elevated levels of inflammatory cytokines and chemokines such as interleukin 6 (IL6) and monocyte chemoattractant protein 1 (MCP-1) (Kiraly et al., 2017). Here, CCL2 is linked to depressive symptom measurement.